Advertisement

Rheumatology International

, Volume 39, Issue 12, pp 2061–2067 | Cite as

Renal flare in class V lupus nephritis: increased risk in patients with tubulointerstitial lesions

  • Oh Chan Kwon
  • Yong Mee Cho
  • Ji Seon Oh
  • Seokchan Hong
  • Chang-Keun Lee
  • Bin Yoo
  • Yong-Gil KimEmail author
Observational Research
  • 103 Downloads

Abstract

The objective of this study is to investigate the risk factors of renal flare in patients with membranous lupus nephritis (class V lupus nephritis). Biopsy-proven pure membranous lupus nephritis patients diagnosed between January 1997 and September 2017 were studied. We assessed and compared the clinical and pathological parameters between patients who experienced renal flare and those who did not. To identify risk factors of renal flare, multivariable Cox proportional hazard regression analysis was performed. Out of the 53 patients with pure membranous lupus nephritis, 17 patients (32.1%) experienced renal flare during a median follow-up of 121.5 months (range 44.4–196.9). Patients who experienced renal flare had significantly higher proportion of tubulointerstitial inflammation (76.5% vs. 36.1%, p = 0.006) and tubular atrophy/interstitial fibrosis (70.6% vs. 27.8%, p = 0.003) at baseline. In multivariable Cox proportional hazard regression analysis, the presence of tubulointerstitial inflammation [adjusted hazard ratio (HR) 5.532, 95% confidence interval (CI) 1.722–17.776, p = 0.004] and tubular atrophy/interstitial fibrosis (adjusted HR 4.328, 95% CI 1.450–12.916, p = 0.009) at baseline was significantly associated with increased risk of renal flare. The presence of tubulointerstitial inflammation and tubular atrophy/interstitial fibrosis is associated with increased risk of renal flare in patients with membranous lupus nephritis.

Keywords

Membranous lupus nephritis Tubulointerstitial inflammation Tubular atrophy Interstitial fibrosis Flare 

Notes

Acknowledgements

The authors would like to thank Enago (http://www.enago.co.kr) for the English language review.

Author contributions

OCK and Y-GK contributed to the conception and design of the study, data collection and analysis, manuscript writing, and final approval of the manuscript. YMC, JSO, SH, C-KL, and BY contributed to data collection and analysis, and critically reviewed the manuscript. All authors read and approved the final version of the manuscript.

Funding

This work was supported by grants from the Asan Institute for Life Sciences (2019-463).

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

All procedures were performed in accordance with the ethical standards of the Institutional Review Board of Asan Medical Center (IRB No: 2018-0137) and with the 1964 Helsinki declaration.

References

  1. 1.
    Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557CrossRefGoogle Scholar
  2. 2.
    Na W, Yi K, Song YS, Park MH (2017) Dissecting the relationships of IgG subclasses and complements in membranous lupus nephritis and idiopathic membranous nephropathy. PLoS One 12:e0174501CrossRefGoogle Scholar
  3. 3.
    Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250CrossRefGoogle Scholar
  4. 4.
    Almaani S, Meara A, Rovin BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12:825–835CrossRefGoogle Scholar
  5. 5.
    Yu F, Haas M, Glassock R, Zhao MH (2017) Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 13:483–495CrossRefGoogle Scholar
  6. 6.
    Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A et al (2017) Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study. Medicine 96:e7429CrossRefGoogle Scholar
  7. 7.
    Silva-Fernandez L, Oton T, Askanase A, Carreira P, Lopez-Longo FJ, Olive A et al (2019) Pure membranous lupus nephritis: description of a cohort of 150 patients and review of the literature. Reumatol Clin 15:34–42CrossRefGoogle Scholar
  8. 8.
    Ward F, Bargman JM (2016) Membranous lupus nephritis: the same, but different. Am J Kidney Dis 68:954–966CrossRefGoogle Scholar
  9. 9.
    Moroni G, Quaglini S, Gravellone L, Gallelli B, Leoni A, Messa P et al (2012) Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin Arthritis Rheum 41:642–651CrossRefGoogle Scholar
  10. 10.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefGoogle Scholar
  11. 11.
    Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMedGoogle Scholar
  12. 12.
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369CrossRefGoogle Scholar
  13. 13.
    Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782CrossRefGoogle Scholar
  14. 14.
    Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH et al (2002) Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46:995–1002CrossRefGoogle Scholar
  15. 15.
    Ciruelo E, de la Cruz J, Lopez I, Gomez-Reino JJ (1996) Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 39:2028–2034CrossRefGoogle Scholar
  16. 16.
    Mejia-Vilet JM, Cordova-Sanchez BM, Arreola-Guerra JM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R (2016) Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus 25:315–324CrossRefGoogle Scholar
  17. 17.
    Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR (2011) Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 63:865–874CrossRefGoogle Scholar
  18. 18.
    Alsuwaida AO (2013) Interstitial inflammation and long-term renal outcomes in lupus nephritis. Lupus 22:1446–1454CrossRefGoogle Scholar
  19. 19.
    Daleboudt GM, Bajema IM, Goemaere NN, van Laar JM, Bruijn JA, Berger SP (2009) The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 24:3712–3717CrossRefGoogle Scholar
  20. 20.
    Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P et al (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37:490–498CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of Internal MedicineUniversity of Ulsan College of Medicine, Asan Medical CenterSeoulSouth Korea
  2. 2.Department of PathologyUniversity of Ulsan College of Medicine, Asan Medical CenterSeoulSouth Korea
  3. 3.Department of Biomedical InformaticsUniversity of Ulsan College of Medicine, Asan Medical CenterSeoulSouth Korea
  4. 4.Division of Rheumatology, Department of Internal MedicineYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations